Abeona Therapeutics Inc.
ABEO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.40
KIRA · Stoqly’s AI analyst, in plain words
- Abeona Therapeutics Inc. had $5.8M of revenue in fiscal 2025. Over five years, revenue changed −10.3% a year on average.
- Its operating margin was −1,536.9%: of every 100 in sales, about −1,537 is left after running the business.
- Abeona Therapeutics Inc. made $71.2M of net profit in fiscal 2025.
- Free cash flow was −$84.3M in fiscal 2025, −1,448.5% of revenue.
- Abeona Therapeutics Inc. has $171M more cash than debt.
Market cap
$251M
P/E
—
Revenue
$5.8M
Net income
$71.2M
Free cash flow
−$84.3M
Operating margin
−1,536.9%
Abeona Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
1,223.1%
Yes. It keeps 1,223.1% of every sale as profit.
Does profit turn into cash?
−1,448.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Abeona Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- ABEONA THERAPEUTICS INC.
- CIK
- 0000318306
Abeona Therapeutics Inc. · ABEO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $3.0M | $1.4M | $3.5M | — | $5.8M |
| Revenue growth | −70.0% | −52.9% | 147.5% | — | — |
| Gross margin | — | — | — | — | 73.7% |
| Operating margin | −2,994.5% | −3,600.8% | −1,346.7% | — | −1,536.9% |
| Net income | −$84.9M | −$39.7M | −$54.2M | −$63.7M | $71.2M |
| Net margin | −2,831.2% | −2,807.4% | −1,548.2% | — | 1,223.1% |
| Diluted EPS | −$0.86 | −$5.53 | −$2.53 | −$1.55 | $1.01 |
| Cash | |||||
| Cash from operations | −$65.7M | −$43.5M | −$37.0M | −$56.0M | −$76.3M |
| Capital expenditure | $4.2M | $0.1M | $0.3M | $2.4M | $8.0M |
| Free cash flow | −$69.8M | −$43.6M | −$37.3M | −$58.5M | −$84.3M |
| FCF margin | −2,327.2% | −3,084.4% | −1,066.9% | — | −1,448.5% |
| Share count change | 6.2% | −92.0% | 172.0% | 92.0% | 61.1% |
| Debt and strength | |||||
| Cash and short-term investments | $45.0M | $52.1M | $52.2M | $97.7M | $191M |
| Debt incl. finance leases | — | — | — | $19.0M | $20.0M |
| Shareholders' equity | $42.4M | $26.8M | $14.8M | $44.0M | $159M |
| Current ratio | 3.4x | 6.8x | 4.2x | 6.1x | 6.9x |
| Interest coverage | −24.6x | −69.2x | −112.8x | −15.3x | −23.9x |
| Returns and quality | |||||
| Return on equity | −117.2% | −114.8% | −260.6% | −216.6% | 70.0% |
| Return on tangible equity | −207.2% | −162.5% | −365.6% | −144.7% | 44.7% |
| Piotroski F-score | 2 | 3 | 2 | — | 4 |
| Altman Z'' | −30.0 | −35.2 | −38.5 | −22.5 | −5.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$3.6M
9 insiders
Of sales under plans
19%
$0.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Abeona Therapeutics Inc. · ABEO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.40 a share, the company is worth $251M.
Source: SEC EDGAR XBRL filings (CIK 0000318306). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.